Victory Capital Management Inc. Boosts Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)

Victory Capital Management Inc. boosted its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 677.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 237,250 shares of the biotechnology company's stock after buying an additional 206,750 shares during the quarter. Victory Capital Management Inc. owned approximately 0.86% of AnaptysBio worth $7,948,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Rhumbline Advisers lifted its holdings in AnaptysBio by 1.8% in the second quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company's stock valued at $745,000 after buying an additional 525 shares during the period. Algert Global LLC lifted its stake in shares of AnaptysBio by 11.8% in the 2nd quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company's stock valued at $255,000 after purchasing an additional 1,078 shares during the period. nVerses Capital LLC boosted its position in shares of AnaptysBio by 700.0% during the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company's stock valued at $54,000 after purchasing an additional 1,400 shares in the last quarter. Values First Advisors Inc. bought a new stake in shares of AnaptysBio during the 3rd quarter valued at about $49,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in AnaptysBio by 81.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company's stock worth $195,000 after purchasing an additional 2,600 shares during the period.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. UBS Group increased their price target on AnaptysBio from $23.00 to $33.00 and gave the stock a "neutral" rating in a report on Wednesday, October 30th. Truist Financial increased their target price on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a "hold" rating in a research note on Thursday, August 15th. Wedbush reaffirmed an "outperform" rating and issued a $42.00 price target on shares of AnaptysBio in a research note on Thursday, November 14th. Guggenheim raised their target price on AnaptysBio from $75.00 to $90.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Finally, HC Wainwright dropped their price target on AnaptysBio from $55.00 to $52.00 and set a "buy" rating on the stock in a research note on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $54.64.

AnaptysBio Trading Up 5.2 %

Shares of NASDAQ:ANAB traded up $1.10 during mid-day trading on Friday, hitting $22.27. 280,289 shares of the company traded hands, compared to its average volume of 351,784. The stock has a 50-day moving average price of $29.78 and a two-hundred day moving average price of $29.71. AnaptysBio, Inc. has a 12-month low of $13.36 and a 12-month high of $41.31. The stock has a market cap of $677.65 million, a P/E ratio of -3.49 and a beta of -0.24.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. As a group, analysts expect that AnaptysBio, Inc. will post -6.02 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the sale, the chief financial officer now directly owns 4,744 shares of the company's stock, valued at approximately $189,333.04. This trade represents a 72.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the sale, the insider now owns 15,398 shares in the company, valued at $595,440.66. This trade represents a 8.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,440 shares of company stock worth $892,936. 33.70% of the stock is owned by insiders.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.